Two large randomized phase 3 trials investigated the efficacy and safety of treatment regimens incorporating CT in combination with Bev and an EGFR inhibitor: the Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) study analyzed CT plus Bev with or without panitumumab, while the CAIRO2 study assessed the efficacy and safety of capecitabine plus oxaliplatin and Bev with or without Cet. This evidence concerns the gene EGFR and colorectal cancer.